Literature DB >> 25858939

Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?

Marielena Baquero-Salamanca1, Angélica María Téllez-Arévalo2, Carlos Calderon-Ospina2.   

Abstract

We present the case of a 34-year-old woman with a history of antiphospholipid syndrome with triple positivity for antiphospholipid antibodies, who had multiple thrombotic events, predominantly pulmonary embolic events, despite treatment with enoxaparin. She is currently on warfarin, with which she has been adequately controlled most of the time, presenting with only one haemorrhagic event consisting of haematuria and prolonged international normalised ratio (INR) without bleeding. This kind of patient represents a challenge for clinicians, particularly due to INR therapeutic targets, which should be higher than recommended in other patients due to the lupus anticoagulant positivity. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25858939      PMCID: PMC4401928          DOI: 10.1136/bcr-2014-209013

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Pharmacogenomic biomarkers: new tools in current and future drug therapy.

Authors:  Sarah C Sim; Magnus Ingelman-Sundberg
Journal:  Trends Pharmacol Sci       Date:  2010-12-22       Impact factor: 14.819

2.  Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation.

Authors:  Siva S Ketha; Rajiv K Pruthi; Robert D McBane; Waldemar E Wysokinski
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

Review 3.  Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants?

Authors:  H Cohen; S J Machin
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

4.  Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins.

Authors:  A Tripodi; V Chantarangkul; M Clerici; B Negri; M Galli; P M Mannucci
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

5.  Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.

Authors:  Terry K Rosborough; Jennifer M Jacobsen; Michele F Shepherd
Journal:  Blood Coagul Fibrinolysis       Date:  2010-04       Impact factor: 1.276

6.  Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.

Authors:  N R Bijsterveld; S Middeldorp; F Berends; H R Büller
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

Review 7.  Antiphospholipid syndrome.

Authors:  Guillermo Ruiz-Irastorza; Mark Crowther; Ware Branch; Munther A Khamashta
Journal:  Lancet       Date:  2010-09-06       Impact factor: 79.321

Review 8.  Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.

Authors:  Ashley Crowl; Anne Schullo-Feulner; Jean Y Moon
Journal:  Ann Pharmacother       Date:  2014-08-07       Impact factor: 3.154

Review 9.  Use of new oral anticoagulants in antiphospholipid syndrome.

Authors:  Deepa Jayakody Arachchillage; Hannah Cohen
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

10.  New oral anticoagulants in thrombotic antiphospholipid syndrome.

Authors:  C B Chighizola; M Moia; P L Meroni
Journal:  Lupus       Date:  2014-10       Impact factor: 2.911

View more
  1 in total

1.  Digital ischaemia secondary to adalimumab-induced antiphospholipid syndrome.

Authors:  Shashank Cheemalavagu; Sara S McCoy; Jason S Knight
Journal:  BMJ Case Rep       Date:  2020-02-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.